MEREO BIOPHARMA (MREO)
(Delayed Data from NSDQ)
$4.15 USD
0.00 (0.00%)
Updated Jul 15, 2024 04:00 PM ET
After-Market: $4.15 0.00 (0.00%) 7:58 PM ET
4-Sell of 5 4
F Value F Growth NA Momentum NA VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MREO 4.15 0.00(0.00%)
Will MREO be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MREO based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MREO
MEREO BIOPHARMA (MREO) Loses -12.74% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Ultragenyx (RARE) Q4 Loss Narrower Than Expected, Revenues Beat
MREO: What are Zacks experts saying now?
Zacks Private Portfolio Services
Ultragenyx's (RARE) Preliminary 2023 Revenues Disappoint
Ultragenyx (RARE) Q3 Earnings and Revenues Miss Estimates
Ultragenyx (RARE) Q2 Loss Wider Than Expected, Revenues Beat
Other News for MREO
Mereo BioPharma price target raised by $2 at Leerink, here's why
Biotech Alert: Searches spiking for these stocks today
Mereo BioPharma Announces Pricing of $50 Million Underwritten Registered Direct Offering of American Depository Shares, Priced At-the-Market
Mereo BioPharma’s Public Offering and Strategic Underwriter Partnership
Baird starts Mereo at outperform, sees alvelestat as underappreciated